Find a paper by its number
Retatrutide claims have numbered links to their papers.
Numbered links take you to the original studies
The drug retatrutide is still being tested. Here you can find the medical papers.
The numbers [1]–[14] beside findings match the links below, which lead to papers or their medical-library listings.
Reviews weigh benefits against the questions still unanswered
Papers [6]–[11] discuss the early findings and remaining questions. Phase 3 means larger tests before an approval request. Papers [12]–[14], published in 2026, compare separate liver studies. Those comparisons can't establish which drug suits you best.
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. ↗
- Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529-544. ↗
- Li W, Zhou Q, Cong Z, et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery. 2024;10:77. ↗
- Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400:1869-1881. ↗
- Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30:2037-2048. ↗
- Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide — A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15:796. ↗
- Neff GW, et al. Shared mechanistic pathways of glucagon signalling: Unlocking its potential for treating obesity, metabolic dysfunction-associated steatotic liver disease, and other cardio-kidney-metabolic conditions. Diabetes, Obesity & Metabolism. 2025;27(12):6869-6883. ↗
- Concepción-Zavaleta MJ, et al. Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review. World Journal of Gastroenterology. 2025;31(37):111435. ↗
- Moiz A, et al. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes: A Systematic Review of Randomized Controlled Trials. Annals of Internal Medicine. 2025;178(2):199-217. ↗
- Zhou Q, et al. Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology. Annual Review of Pharmacology and Toxicology. 2025;65(1):191-213. ↗
- Nicze M, et al. Resistant and Refractory Obesity: The Complexity of Anti-Obesity Therapy Failure. International Journal of Molecular Sciences. 2026;27(6):2539. ↗
- Andonie CR, et al. Comparative Analysis of Glucagon Receptor Agonists vs. Resmetirom in MASLD and MASH: Network Meta-Analysis of Clinical Trials. Endocrinology, Diabetes & Metabolism. 2026. ↗
- Lu X, et al. Glucagon-like peptide-1 and dual/triple receptor agonists in the treatment of metabolic dysfunction-associated steatotic liver disease: advances in mechanistic research. Frontiers in Medicine. 2026. ↗
- Abulehia A, et al. Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials. Endocrinology, Diabetes & Metabolism. 2026. ↗